Muthu Veera Kumaran

Professor

UAMS

Also affiliated: University of Arkansas Medical Center (2026)

2 h-index 11 pubs 8 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Muthu V. Kumaran's research focuses on dermatological conditions, with a particular emphasis on vitiligo and related pigmentary disorders. He has investigated various treatment modalities for localized vitiligo, including topical calcipotriol and betamethasone dipropionate, as well as oral corticosteroid minipulse and methotrexate for unstable vitiligo. His work also includes evaluating dermatoscopic and histopathological correlations in acquired dermal macular hyperpigmentation. Kumaran has explored the psychological impact of pigmentary disorders and has published on the global effects of the COVID-19 pandemic on chronic urticaria management. His research network includes collaborators such as Mamatha Gaddam, Ankur Varma, César Sánchez, and Nishanth Thalambedu at the University of Arkansas for Medical Sciences, with whom he has co-authored multiple publications.

Metrics

h-index: 2
Publications: 11
Citations: 8

Positions

Professor 2011–present

Post Graduate Institute of Medical Education and Research School of Public Health Department of Community Medicine Dermatology ORCID
Professor

Post Graduate Institute of Medical Education and Research School of Public Health Department of Community Medicine: Chandigarh, Punjab, IN Dermatology Venereology and Leprology ORCID
Professor publications 2024–2026

University of Arkansas for Medical Sciences ORCID
Assistant Professor 2011–2014

Post Graduate Institute of Medical Education and Research Dermatology ORCID
Associate Professor 2007–2011

St John's Medical college and Hospital Dermatology ORCID
Assistant Professor 2004–2007

St John's Medical college and Hospital Dermatology ORCID

Selected Publications

CLL-888: Efficacy and Safety of CAR-T Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
POSTER: CLL-888: Efficacy and Safety of CAR-T Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence. (2026)

DOI OpenAlex
Social vulnerability index as an independent poor prognostic factor in patients with chronic hematological malignancies in Arkansas. (2026)

DOI OpenAlex
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL (2026)

Blood 3 citations DOI OpenAlex
Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis (2025)

Blood 2 citations DOI OpenAlex
Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world (2025)

Blood 2 citations DOI OpenAlex
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia (2025)

Blood Advances 4 citations DOI OpenAlex
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (2025)

Bone Marrow Transplantation 1 citation DOI OpenAlex
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)

Diagnostics 8 citations DOI OpenAlex
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement (2025)

Blood Advances 7 citations DOI OpenAlex
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy (2025)

Blood Advances 15 citations DOI OpenAlex
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)

Cancers 5 citations DOI OpenAlex
Impact of Response to Bridging Therapy on Outcomes of CAR-T Therapy in Relapsed/Refractory DLBCL: A Single Center Retrospective Analysis (2024)

DOI OpenAlex
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above (2024)

Blood 3 citations DOI OpenAlex